Skip to main content
TipRanks
Go Ultimate75% OFF

Ovid Therapeutics (OVID) Stock Price & Analysis

1,782 Followers

OVID Stock Chart & Stats

$2.34$0.08(3.54%)
At close: 4:00 PM EST
$2.25$2.5$2.75Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$2.19 - $2.38
52-Week Range
$1.21 - $3.11
Previous Close
$2.26
Volume
N/A
Average Volume (3M)
2.34M
Market Cap
$441.63M
Enterprise Value
$381.28M
Total Cash (Recent Filing)
$136.60M
Total Debt (Recent Filing)
$12.35M
Price to Earnings (P/E)
―
Beta
1.71
Next Earnings
Mar 15, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low debt relative to equity limits interest and refinancing pressure, preserving financial flexibility for clinical development and partnerships. This balance-sheet structure gives Ovid more capacity to absorb operating volatility than a highly leveraged biotech, provided losses do not continue eroding equity.

Asset Base

A sizable asset base provides a financial cushion while Ovid advances its pipeline through clinical development. That resource base can support operations and preserve strategic options over the next several quarters, although its durability ultimately depends on the pace of cash consumption and loss reduction.

Rare-neurology Focus

A focused pipeline in rare neurological and neurodevelopmental disorders can support specialized scientific expertise and clearer therapeutic positioning. Concentration in these areas may help Ovid build differentiated development capabilities and pursue partnership opportunities around unmet medical needs over time.

Bears Say

Persistent Cash Burn

Sustained negative operating and free cash flow means Ovid is consuming substantial resources to fund its business rather than self-financing operations. Continued burn can reduce the balance-sheet cushion and increase reliance on existing cash or future financing as clinical work proceeds.

Deep Operating Losses

Minimal revenue alongside a large net loss indicates that Ovid has not yet established durable earnings power. Persistent losses can weaken equity over time, constrain investment flexibility, and make progress dependent on successful development milestones or additional funding.

Revenue Volatility

Volatile and declining revenue makes Ovid’s financial base difficult to forecast and underscores its dependence on episodic collaboration-related income rather than recurring product sales. This reduces visibility into funding capacity and leaves results sensitive to development and partnership timing.

Ovid Therapeutics News

OVID FAQ

What was Ovid Therapeutics’s price range in the past 12 months?
Ovid Therapeutics lowest stock price was $1.21 and its highest was $3.11 in the past 12 months.
What is Ovid Therapeutics’s market cap?
Ovid Therapeutics’s market cap is $441.63M.
When is Ovid Therapeutics’s upcoming earnings report date?
Ovid Therapeutics’s next earnings report is estimated for Mar 15, 2027 (not yet confirmed), which is in 115 days.
How were Ovid Therapeutics’s earnings last quarter?
Ovid Therapeutics released its earnings results on Nov 10, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.085 by -$0.015.
Is Ovid Therapeutics overvalued?
According to Wall Street analysts Ovid Therapeutics’s price is currently Undervalued.
Does Ovid Therapeutics pay dividends?
Ovid Therapeutics does not currently pay dividends.
What is Ovid Therapeutics’s EPS estimate?
Ovid Therapeutics’s EPS estimate is -0.10.
How many shares outstanding does Ovid Therapeutics have?
Ovid Therapeutics has 188,731,920 shares outstanding.
What happened to Ovid Therapeutics’s price movement after its last earnings report?
Ovid Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.085. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Ovid Therapeutics?
Hedge funds hold Ovid Therapeutics shares: the largest hedge-fund position in Ovid Therapeutics is 72,325,999 shares, and hedge funds decreased their holdings by 3.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology